Mechanisms of immune activation and regulation: lessons from melanoma

被引:142
作者
Kalaora, Shelly [1 ]
Nagler, Adi [1 ]
Wargo, Jennifer A. [2 ,3 ]
Samuels, Yardena [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
基金
以色列科学基金会; 欧洲研究理事会;
关键词
FECAL MICROBIOTA TRANSPLANT; DESORPTION IONIZATION-TIME; AUTOLOGOUS T-CELLS; RNA GENE DATABASE; TUMOR MICROENVIRONMENT; FUSOBACTERIUM-NUCLEATUM; METASTATIC MELANOMA; CLINICAL-RESPONSE; PD-1; BLOCKADE; ANTITUMOR IMMUNITY;
D O I
10.1038/s41568-022-00442-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively, particularly in terms of the immune response to tumours, and has been used as a model for the development of immunotherapy. This is due, in part, to the high mutational burden observed in melanomas, which increases both their immunogenicity and the infiltration of immune cells into the tumours, compared with other types of cancers. The immune response to melanomas involves a complex set of components and interactions. As the tumour evolves, it accumulates an increasing number of genetic and epigenetic alterations, some of which contribute to the immunogenicity of the tumour cells and the infiltration of immune cells. However, tumour evolution also enables the development of resistance mechanisms, which, in turn, lead to tumour immune escape. Understanding the interactions between melanoma tumour cells and the immune system, and the evolving changes within the melanoma tumour cells, the immune system and the microenvironment, is essential for the development of new cancer therapies. However, current research suggests that other extrinsic factors, such as the microbiome, may play a role in the immune response to melanomas. Here, we review the mechanisms underlying the immune response in the tumour and discuss recent advances as well as strategies for treatment development. This Review discusses the mechanisms underlying the immune response to melanomas, as well as the mechanisms of response and resistance of these tumours to immunotherapies. The lessons learned in melanoma may apply to other tumour types.
引用
收藏
页码:195 / 207
页数:13
相关论文
共 50 条
  • [21] Immune Checkpoint Therapy in Melanoma
    Callahan, Margaret K.
    CANCER JOURNAL, 2016, 22 (02) : 73 - 80
  • [22] Update on immune therapy in melanoma
    Wang, Daniel Y.
    Johnson, Douglas B.
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (08): : 799 - 808
  • [23] The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
    Marco, Tucci
    Anna, Passarelli
    Annalisa, Todisco
    Francesco, Mannavola
    Stefania, Stucci Luigia
    Stella, D'Oronzo
    Michele, Rossini
    Marco, Taurisano
    Loreto, Gesualdo
    Franco, Silvestris
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [24] Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications
    Aivazian, Karina
    PATHOLOGY, 2023, 55 (02) : 227 - 235
  • [25] Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
    Vukadin, Sonja
    Khaznadar, Farah
    Kizivat, Tomislav
    Vcev, Aleksandar
    Smolic, Martina
    BIOMEDICINES, 2021, 9 (07)
  • [26] Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
    Marzagalli, Monica
    Ebelt, Nancy D.
    Manuel, Edwin R.
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 236 - 250
  • [27] Topical Imiquimod Induces Immune Activation and Regressions of Cutaneous Melanoma Metastases
    Salerno, Elise P.
    Wang, Ena
    Marincola, Franco
    Slingluff, Craig L.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 751 - 752
  • [28] The regulation of immune checkpoints by the hypoxic tumor microenvironment
    Hu, Min
    Li, Yongfu
    Lu, Yuting
    Wang, Miao
    Li, Yingrui
    Wang, Chaoying
    Li, Qin
    Zhao, Hong
    PEERJ, 2021, 9
  • [29] Mechanisms of immunotherapy resistance: lessons from glioblastoma
    Jackson, Christopher M.
    Choi, John
    Lim, Michael
    NATURE IMMUNOLOGY, 2019, 20 (09) : 1100 - 1109
  • [30] Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma
    Leonard-Murali, Shravan
    Kammula, Udai S.
    IMMUNOTHERAPY, 2025, 17 (04) : 283 - 291